Literature DB >> 6293738

Stimulation of slow action potentials in guinea pig papillary muscle cells by intracellular injection of cAMP, Gpp(NH)p, and cholera toxin.

T Li, N Sperelakis.   

Abstract

To test the hypothesis that intracellular cAMP has a regulatory role in cardiac slow channel function, intracellular pressure injections of cAMP and adenylate cyclase activators, Gpp(NH)p and cholera toxin, were carried out. Guinea pig papillary muscles were depolarized to about -45 mV by superfusion with 22 mM K+-Tyrode's solution to inactivate the fast Na+ channels. Induction of slow action potentials or enhancement of ongoing slow action potentials was observed in about 70% of all cells in which a successful intracellular injection of the testing compounds was obtained. The slow AP is highly dependent on slow inward current and is known to be enhanced by catecholamines. The effect of the injected cyclic nucleotides and related compounds occurred within 3 minutes after starting the injection, whereas superfusion with these compounds (dibutyryl cAMP was used in place of cAMP) required 10-30 minutes to show an effect. This difference is attributed to the intracellular injection of the compound. The effect on stimulating slow action potentials persisted (greater than 5 minutes) after termination of the application of either Gpp(NH)p or cholera toxin, indicating the long-lasting nature of their action. The effect of the cAMP injections decayed within 1 minute. Intracellular injection of 5'-AMP was without effect. These results support the view that a causal relationship exists between intracellular cAMP level and slow channel function. Phosphorylation of a protein constituent of the slow channel by a cAMP-dependent protein kinase may be involved.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6293738     DOI: 10.1161/01.res.52.1.111

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

Review 1.  Regulation of ion channels in myocardial cells and protection of ischemic myocardium.

Authors:  N Sperelakis; M Sunagawa; H Yokoshiki; T Seki; M Nakamura
Journal:  Heart Fail Rev       Date:  2000-06       Impact factor: 4.214

Review 2.  Properties of calcium channels in cardiac muscle and vascular smooth muscle.

Authors:  N Sperelakis
Journal:  Mol Cell Biochem       Date:  1990-12-20       Impact factor: 3.396

3.  Evidence for inhibition by ICS 205-930 and stimulation by BRL 34915 of K+ conductance in cardiac muscle.

Authors:  G Scholtysik
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-06       Impact factor: 3.000

4.  On the relationship between V max of slow responses and Ca-current availability in whole-cell clamped guinea pig heart cells.

Authors:  C O Malécot; W Trautwein
Journal:  Pflugers Arch       Date:  1987-09       Impact factor: 3.657

5.  Intracrine action of angiotensin II in the intact ventricle of the failing heart: angiotensin II changes cardiac excitability from within.

Authors:  Walmor C De Mello
Journal:  Mol Cell Biochem       Date:  2011-07-09       Impact factor: 3.396

Review 6.  Regulation of slow calcium channels of myocardial cells and vascular smooth muscle cells by cyclic nucleotides and phosphorylation.

Authors:  N Sperelakis; Z Xiong; G Haddad; H Masuda
Journal:  Mol Cell Biochem       Date:  1994-11-23       Impact factor: 3.396

7.  Regulation of Ca2+ influx in myocardial cells by beta adrenergic receptors, cyclic nucleotides, and phosphorylation.

Authors:  N Sperelakis; G M Wahler
Journal:  Mol Cell Biochem       Date:  1988 Jul-Aug       Impact factor: 3.396

Review 8.  Regulation of the slow Ca++ channels of myocardial cells.

Authors:  N Sperelakis; Y Katsube; H Yokoshiki; H Sada; K Sumii
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

9.  Effects of amrinone on the transmembrane action potential of rabbit sinus node pacemaker cells.

Authors:  I Kodama; N Kondo; S Shibata
Journal:  Br J Pharmacol       Date:  1983-11       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.